Skip to main content
Erschienen in: Hepatology International 5/2018

16.08.2018 | Review Article

Management of acute-on-chronic liver failure: an algorithmic approach

verfasst von: Shiv Kumar Sarin, Ashok Choudhury

Erschienen in: Hepatology International | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Acute-on-chronic liver failure (ACLF) is a distinct syndrome of liver failure in a patient with chronic liver disease presenting with jaundice, coagulopathy and ascites and/or hepatic encephalopathy, developing following an acute hepatic insult and associated with high 28-day mortality. The definition though lacks global consensus, excludes patients with known distinct entities such as acute liver failure and those with end-stage liver disease. The initial Systemic Inflammatory Response Syndrome (SIRS) because of cytokine storm in relation to acute insult and/or subsequent development of sepsis due to immunoparalysis leads to extrahepatic organ failure. These cascades of events progress through a ‘Golden Window’ period of about 7 days, subsequent to which majority of the patients develop complications, such as sepsis and extrahepatic organ failure. Prevention of sepsis, support of organs and management of organ failure (commonly hepatic, renal, cerebral, coagulation) and early referral for transplant is crucial. The APASL ACLF research consortium (AARC) liver failure score is a dynamic prognostic model for management decisions and is superior to existing models. Aggressive multidisciplinary approach can lead to a transplant-free survival in nearly half of the cases. The present review provides an algorithmic approach to management of organ failure, sepsis prevention, use of dynamic prognostic models for management decision and is aimed to improve the skills for managing and improving the outcomes of such critically ill patients.
Literatur
1.
Zurück zum Zitat Sarin S, Chandan K, Zaigham A, APASL ACLF working partyl, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2014;8:453–471CrossRef Sarin S, Chandan K, Zaigham A, APASL ACLF working partyl, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2014;8:453–471CrossRef
2.
Zurück zum Zitat Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep 2016;18(12):61 (PMID: 27747458) CrossRef Sarin SK, Choudhury A. Acute-on-chronic liver failure. Curr Gastroenterol Rep 2016;18(12):61 (PMID: 27747458) CrossRef
3.
Zurück zum Zitat Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Nat Rev Gastroenterol Hepatol 2016;13(3):131–149CrossRef Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Nat Rev Gastroenterol Hepatol 2016;13(3):131–149CrossRef
4.
Zurück zum Zitat Choudhury A, Jindal A, Sarin SK, for the APASL ACLF Working Party et al. Liver failure determines the outcome in patients of Acute-on-Chronic Liver Failure (ACLF)-comparison of APASLACLF Research Consortium (AARC) and CLIF-SOFA model. Hepatol Int 2017;11(5):461–471.CrossRef Choudhury A, Jindal A, Sarin SK, for the APASL ACLF Working Party et al. Liver failure determines the outcome in patients of Acute-on-Chronic Liver Failure (ACLF)-comparison of APASLACLF Research Consortium (AARC) and CLIF-SOFA model. Hepatol Int 2017;11(5):461–471.CrossRef
5.
Zurück zum Zitat Choudhury AK, Sharma M, Mehtab M, Sarin SK, for APASL ACLF Working party, et al. The decision for liver transplant in acute-on-chronic liver failure (ACLF)-first week is the crucial period-analysis of the APASL ACLF Research Consortium (AARC) prospective data of 1021 patients. J Hepatol 2016;64:151CrossRef Choudhury AK, Sharma M, Mehtab M, Sarin SK, for APASL ACLF Working party, et al. The decision for liver transplant in acute-on-chronic liver failure (ACLF)-first week is the crucial period-analysis of the APASL ACLF Research Consortium (AARC) prospective data of 1021 patients. J Hepatol 2016;64:151CrossRef
6.
Zurück zum Zitat Sarin SK, Kumar A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269–282CrossRef Sarin SK, Kumar A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009;3:269–282CrossRef
7.
Zurück zum Zitat Moreau R, Jalan R, Gines P, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437CrossRef Moreau R, Jalan R, Gines P, et al. Acute on chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437CrossRef
8.
Zurück zum Zitat Choudhury A, Sharma M, Sarin SK, for APASL ACLF Working party, et al. Etiology, time frame and spectrum of decompensation in 6236 patients of cirrhosis liver across Asia: a multinational study from APASL ACLF Research Consortium (AARC). J Hepatol 2017;66:S63–S94CrossRef Choudhury A, Sharma M, Sarin SK, for APASL ACLF Working party, et al. Etiology, time frame and spectrum of decompensation in 6236 patients of cirrhosis liver across Asia: a multinational study from APASL ACLF Research Consortium (AARC). J Hepatol 2017;66:S63–S94CrossRef
10.
Zurück zum Zitat Hou W, Li J, Wang JH, Meng QH. Carbohydrate-predominant LES is associated with increases in fasting carbohydrate oxidation, REE and reductions in fat oxidation in adults with ACLF. Therapeutic strategies utilizing LES may promote improved nutritional status in adults with ACLF. Eur J Clin Nutr 2013;67:1251–126CrossRef Hou W, Li J, Wang JH, Meng QH. Carbohydrate-predominant LES is associated with increases in fasting carbohydrate oxidation, REE and reductions in fat oxidation in adults with ACLF. Therapeutic strategies utilizing LES may promote improved nutritional status in adults with ACLF. Eur J Clin Nutr 2013;67:1251–126CrossRef
11.
Zurück zum Zitat Krenitsky J. Nutrition for patients with hepatic failure. Pract Gastroenterol 2003;6:23–42 Krenitsky J. Nutrition for patients with hepatic failure. Pract Gastroenterol 2003;6:23–42
13.
Zurück zum Zitat Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous re- activation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774–780CrossRef Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous re- activation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011;53:774–780CrossRef
14.
Zurück zum Zitat Jindal A, Kumar M, Sarin SK. A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B. J Viral Hepat 2015;22(Suppl. 2):1–18 Jindal A, Kumar M, Sarin SK. A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B. J Viral Hepat 2015;22(Suppl. 2):1–18
17.
Zurück zum Zitat Mathurin P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–60CrossRef Mathurin P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255–60CrossRef
18.
Zurück zum Zitat Louvet A, Wartel F, Castel H, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541–548CrossRef Louvet A, Wartel F, Castel H, Mathurin P. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137:541–548CrossRef
19.
Zurück zum Zitat Mathurin P, Moreno C, Samuel D, Pruvot FR, Vallée JC. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–800CrossRef Mathurin P, Moreno C, Samuel D, Pruvot FR, Vallée JC. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–800CrossRef
21.
Zurück zum Zitat Mambro AJ, et al. In vitro steroid resistance correlates with out- come in severe alcoholic hepatitis. Hepatology 2011;53:1316–1322CrossRef Mambro AJ, et al. In vitro steroid resistance correlates with out- come in severe alcoholic hepatitis. Hepatology 2011;53:1316–1322CrossRef
26.
Zurück zum Zitat Anand L, Choudhury A, Bihari C, Sharma BC, Sarin SK, APASL ACLF working party. Flare of Autoimmune Hepatitis as a cause of acute on chronic liver failure and its response to steroid therapy. Hepatology 2017;(Suppl):661–662. (AASLD abstract). Anand L, Choudhury A, Bihari C, Sharma BC, Sarin SK, APASL ACLF working party. Flare of Autoimmune Hepatitis as a cause of acute on chronic liver failure and its response to steroid therapy. Hepatology 2017;(Suppl):661–662. (AASLD abstract).
27.
Zurück zum Zitat Yeoman AD, Westbrook RH, Portmann C, O’Grady OJ, Harrison PM, Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53:926–934CrossRef Yeoman AD, Westbrook RH, Portmann C, O’Grady OJ, Harrison PM, Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53:926–934CrossRef
29.
Zurück zum Zitat Larsen FS, Vainer B, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol 2007;13:3232–3236CrossRef Larsen FS, Vainer B, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol 2007;13:3232–3236CrossRef
30.
Zurück zum Zitat Hennes EM, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J. Gastroenterol 2008;103:3063–3070CrossRef Hennes EM, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J. Gastroenterol 2008;103:3063–3070CrossRef
32.
Zurück zum Zitat Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute- on-chronic liver failure. Dig Liver Dis 2012;44(2):166–1671CrossRef Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute- on-chronic liver failure. Dig Liver Dis 2012;44(2):166–1671CrossRef
33.
Zurück zum Zitat Selva Rajoo A, Lim SG, Phyo WW, Tun T, Dan YY, Lee YM, Low HC, et al. Acute-on-chronic liver failure in a multi-ethnic Asian city: a comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions. World J Hepatol 2017;9(28):1133–1140. https://doi.org/10.4254/wjh.v9.i28.1133 CrossRef Selva Rajoo A, Lim SG, Phyo WW, Tun T, Dan YY, Lee YM, Low HC, et al. Acute-on-chronic liver failure in a multi-ethnic Asian city: a comparison of patients identified by Asia-Pacific Association for the Study of the Liver and European Association for the Study of the Liver definitions. World J Hepatol 2017;9(28):1133–1140. https://​doi.​org/​10.​4254/​wjh.​v9.​i28.​1133 CrossRef
34.
Zurück zum Zitat Vyas TS, Maiwall R, Jinadal A, Sarin SK. Goal directed ammonia lowering therapy in acute on chronic liver failure (ACLF) with hepatic encephalopathy (HE): a randomized trial (clinicaltrials.gov identifier: NCT02321371). Hepatol J 2017;7(1):S19–S2 (in press).CrossRef Vyas TS, Maiwall R, Jinadal A, Sarin SK. Goal directed ammonia lowering therapy in acute on chronic liver failure (ACLF) with hepatic encephalopathy (HE): a randomized trial (clinicaltrials.gov identifier: NCT02321371). Hepatol J 2017;7(1):S19–S2 (in press).CrossRef
35.
Zurück zum Zitat Maiwall R, Kumar S, Vashishtha C, Kumar M, Garg H, Nayak SL, et al. Acute kidney injury (AKI) in patients with Acute-on-chronic liver failure (ACLF) is different from patients with cirrhosi. Hepatology 2015;58(4 Suppl):36A–91A Maiwall R, Kumar S, Vashishtha C, Kumar M, Garg H, Nayak SL, et al. Acute kidney injury (AKI) in patients with Acute-on-chronic liver failure (ACLF) is different from patients with cirrhosi. Hepatology 2015;58(4 Suppl):36A–91A
37.
Zurück zum Zitat Maiwall R, Choudhury AK, Devarbhavi H, ShivK, Sarin K, APASL ACLF Working Party. Dynamic AARC-AKI score determines extra- renal organ failures and bacterial infection in patients with acute on chronic liver failure. Hepatology 2017; 661 (Suppl) (AASLD abstract) Maiwall R, Choudhury AK, Devarbhavi H, ShivK, Sarin K, APASL ACLF Working Party. Dynamic AARC-AKI score determines extra- renal organ failures and bacterial infection in patients with acute on chronic liver failure. Hepatology 2017; 661 (Suppl) (AASLD abstract)
38.
Zurück zum Zitat Maiwall R, Chandel SS, Wani Z, Kumar S, Sarin SK. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci 2016;61(3):920–929CrossRef Maiwall R, Chandel SS, Wani Z, Kumar S, Sarin SK. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci 2016;61(3):920–929CrossRef
39.
Zurück zum Zitat Arora V, Maiwall R, Choudhury A, Jain P, Kumar G, Sarin SK. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. J Hepatol 2017;66(1):563CrossRef Arora V, Maiwall R, Choudhury A, Jain P, Kumar G, Sarin SK. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF. J Hepatol 2017;66(1):563CrossRef
40.
Zurück zum Zitat Slack AJ, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int 2014;34:42–48CrossRef Slack AJ, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int 2014;34:42–48CrossRef
41.
Zurück zum Zitat Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012;33:144–148CrossRef Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012;33:144–148CrossRef
43.
Zurück zum Zitat Choudhury A, Kumar M, Sharma BC, Maiwall R, Pamecha V, Moreau R, Chawla YK. Systemic inflammatory response syndrome in acute on chronic liver failure- relevance of ‘Golden Window’—a prospective study. J Gastroenterol Hepatol 2017. https://doi.org/10.1111/jgh.13799 (Epub ahead of print PMID: 28374414) CrossRefPubMed Choudhury A, Kumar M, Sharma BC, Maiwall R, Pamecha V, Moreau R, Chawla YK. Systemic inflammatory response syndrome in acute on chronic liver failure- relevance of ‘Golden Window’—a prospective study. J Gastroenterol Hepatol 2017. https://​doi.​org/​10.​1111/​jgh.​13799 (Epub ahead of print PMID: 28374414) CrossRefPubMed
44.
Zurück zum Zitat O’Brien AJ, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med. 2014;20:518–523CrossRef O’Brien AJ, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med. 2014;20:518–523CrossRef
46.
Zurück zum Zitat Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358(9):877–887 (PMID: 18305265) CrossRef Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358(9):877–887 (PMID: 18305265) CrossRef
48.
49.
Zurück zum Zitat Garg H, Kumar A, Sharma BC, Sarin SK, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol 2013;28:1361–7CrossRef Garg H, Kumar A, Sharma BC, Sarin SK, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol 2013;28:1361–7CrossRef
50.
Zurück zum Zitat Kainth S, Sharma MK, Choudhury AK, Anand L, Jindal A, Kumar G, Jain P, et al. Efficacy and safety of carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices – a placebo control open label randomised trial (NCT02583698). Hepatology 2017; 66(1 Suppl). (AASLD abstract) Kainth S, Sharma MK, Choudhury AK, Anand L, Jindal A, Kumar G, Jain P, et al. Efficacy and safety of carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices – a placebo control open label randomised trial (NCT02583698). Hepatology 2017; 66(1 Suppl). (AASLD abstract)
51.
Zurück zum Zitat Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y. Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. J Gastroenterol Hepatol 2015;30(3):575–581CrossRef Agrawal S, Duseja A, Gupta T, Dhiman RK, Chawla Y. Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. J Gastroenterol Hepatol 2015;30(3):575–581CrossRef
52.
Zurück zum Zitat Kalambokis G, Manousou P, Patch D, Burroughs AK. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications—a systematic review. J Hepatol 2007;47:284–294CrossRef Kalambokis G, Manousou P, Patch D, Burroughs AK. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications—a systematic review. J Hepatol 2007;47:284–294CrossRef
53.
Zurück zum Zitat Rastogi A, Kumar A, Gondal R, Sarin SK, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459:121–127CrossRef Rastogi A, Kumar A, Gondal R, Sarin SK, et al. Liver histology as predictor of outcome in patients with acute-on-chronic liver failure (ACLF). Virchows Arch 2011;459:121–127CrossRef
54.
Zurück zum Zitat Li H, et al. Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J Hepatol 2015;63:50–59CrossRef Li H, et al. Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation. J Hepatol 2015;63:50–59CrossRef
55.
Zurück zum Zitat Chan CA, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int 2009;3:571–581CrossRef Chan CA, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int 2009;3:571–581CrossRef
60.
Zurück zum Zitat Gustot T, Fernandez J, Garcia E, for CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243–252 Gustot T, Fernandez J, Garcia E, for CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62(1):243–252
61.
Zurück zum Zitat Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880CrossRef Wong RJ, Aguilar M, Gish RG, Cheung R, Ahmed A. The impact of pretransplant hepatic encephalopathy on survival following liver transplantation. Liver Transpl 2015;21:873–880CrossRef
62.
63.
Zurück zum Zitat Cheng CH, Lee CF, Soong RS, Wu TH, Chan KM, Chou HS, Wu TJ, et al. Risk factors and clinical outcomes of ventilator-associated pneumonia in patients on the liver transplant waiting list. Transpl Proc 2012;44(3):762–764CrossRef Cheng CH, Lee CF, Soong RS, Wu TH, Chan KM, Chou HS, Wu TJ, et al. Risk factors and clinical outcomes of ventilator-associated pneumonia in patients on the liver transplant waiting list. Transpl Proc 2012;44(3):762–764CrossRef
64.
Zurück zum Zitat Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, Cho HD, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high- model for end-stage liver disease score patients. Am J Transpl 2017;17(7):1833–1842 (PMID: 28097804]-64).CrossRef Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, Cho HD, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high- model for end-stage liver disease score patients. Am J Transpl 2017;17(7):1833–1842 (PMID: 28097804]-64).CrossRef
68.
Zurück zum Zitat Maiwall R, Maras JS, Nayak S, Sarin SK. Liver dialysis in acute- on-chronic liver failure: current and future 3 perspectives. International 2014;8(2 Supplement):505–513 Maiwall R, Maras JS, Nayak S, Sarin SK. Liver dialysis in acute- on-chronic liver failure: current and future 3 perspectives. International 2014;8(2 Supplement):505–513
69.
Zurück zum Zitat Wan YM, Li YH, Xu ZY, Yang J, Yang LH, Xu Y, Yang JH. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entecavir: a prospective study. J Clin Apher. 2017;32(6):453–461. https://doi.org/10.1002/jca.21535 (Epub 2017 Mar 17) CrossRefPubMed Wan YM, Li YH, Xu ZY, Yang J, Yang LH, Xu Y, Yang JH. Therapeutic plasma exchange versus double plasma molecular absorption system in hepatitis B virus-infected acute-on-chronic liver failure treated by entecavir: a prospective study. J Clin Apher. 2017;32(6):453–461. https://​doi.​org/​10.​1002/​jca.​21535 (Epub 2017 Mar 17) CrossRefPubMed
70.
Zurück zum Zitat Chen JJ, Huang JR, Yang Q, Xu XW, Liu XL, Hao SR, Wang HF, et al. Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int 2016;15(3):275–281CrossRef Chen JJ, Huang JR, Yang Q, Xu XW, Liu XL, Hao SR, Wang HF, et al. Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China. Hepatobiliary Pancreat Dis Int 2016;15(3):275–281CrossRef
71.
Zurück zum Zitat Kribben A, Gerken G, Haag S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on- chronic liver failure. Gastroenterology. 2012;142:782.e3–789.e3CrossRef Kribben A, Gerken G, Haag S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on- chronic liver failure. Gastroenterology. 2012;142:782.e3–789.e3CrossRef
72.
Zurück zum Zitat Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153–1162CrossRef Banares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013;57:1153–1162CrossRef
73.
Zurück zum Zitat Vaid A, Chweich H, Balk EM, Jaber BL. Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis. ASAIO J 2012;58(1):51–59CrossRef Vaid A, Chweich H, Balk EM, Jaber BL. Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis. ASAIO J 2012;58(1):51–59CrossRef
75.
Zurück zum Zitat Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression. Exp Ther Med 2013;6(4):929–936 (Epub 2013 Jul PubMedPMID: 24137292; PubMed Central PMCID: PMC3797301) CrossRef Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression. Exp Ther Med 2013;6(4):929–936 (Epub 2013 Jul PubMedPMID: 24137292; PubMed Central PMCID: PMC3797301) CrossRef
77.
Zurück zum Zitat Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Exp Ther Med 2013;6(4):929–936CrossRef Zheng Z, Li X, Li Z, Ma X. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: a meta-analysis and meta-regression. Exp Ther Med 2013;6(4):929–936CrossRef
78.
Zurück zum Zitat Pless G, Sauer IM. Bioartificial  liver:  current  status. Transpl Proc 2005;37:3893–3895CrossRef Pless G, Sauer IM. Bioartificial  liver:  current  status. Transpl Proc 2005;37:3893–3895CrossRef
81.
Zurück zum Zitat Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatol 2013;59(1):183–185 (PMID:23353868) CrossRef Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatol 2013;59(1):183–185 (PMID:23353868) CrossRef
82.
Zurück zum Zitat Garg V, Garg H, Khan A, Sarin SK, et al. Granulocyte-colony stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142:505–512CrossRef Garg V, Garg H, Khan A, Sarin SK, et al. Granulocyte-colony stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142:505–512CrossRef
83.
Zurück zum Zitat Singh V, Sharma AK, Sharma N, Sharma R. Granulocyte colony- stimulating factor in severe alcoholic hepatitis : a randomized pilot study. Am J Gastroenterol 2014;109:1417–1423CrossRef Singh V, Sharma AK, Sharma N, Sharma R. Granulocyte colony- stimulating factor in severe alcoholic hepatitis : a randomized pilot study. Am J Gastroenterol 2014;109:1417–1423CrossRef
84.
Zurück zum Zitat Duan XZ, Liu FF, Tong JJ, Hu JH. Granulocyte-colony stimulat- ing factor therapy improves survival in patients with hepatitis B virus-associated acute on- chronic liver failure. World J Gastroenterol 2013;19(7):1104–1110CrossRef Duan XZ, Liu FF, Tong JJ, Hu JH. Granulocyte-colony stimulat- ing factor therapy improves survival in patients with hepatitis B virus-associated acute on- chronic liver failure. World J Gastroenterol 2013;19(7):1104–1110CrossRef
85.
Zurück zum Zitat Kedarisetty CK, Anand L, Bhatia V, Sarin SK. Combination of granulocyte colony-stimulating factor and erythropoietin im- proves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015;148(7):1362.e7–1370.e7CrossRef Kedarisetty CK, Anand L, Bhatia V, Sarin SK. Combination of granulocyte colony-stimulating factor and erythropoietin im- proves outcomes of patients with decompensated cirrhosis. Gastroenterology 2015;148(7):1362.e7–1370.e7CrossRef
87.
Zurück zum Zitat Wang F, Zhou L, Ma X, Ma W, Wang C, Lu Y, Chen Y, et al. Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study. Transpl Proc 2014;46(1):192–198CrossRef Wang F, Zhou L, Ma X, Ma W, Wang C, Lu Y, Chen Y, et al. Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study. Transpl Proc 2014;46(1):192–198CrossRef
88.
Zurück zum Zitat Shi M, Zhang Z, Jin L, Liu Z, Wang FS, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012;1(10):725–731CrossRef Shi M, Zhang Z, Jin L, Liu Z, Wang FS, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012;1(10):725–731CrossRef
89.
90.
Metadaten
Titel
Management of acute-on-chronic liver failure: an algorithmic approach
verfasst von
Shiv Kumar Sarin
Ashok Choudhury
Publikationsdatum
16.08.2018
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2018
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-018-9887-5

Weitere Artikel der Ausgabe 5/2018

Hepatology International 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.